Perspective Therapeutics (CATX) Interest & Investment Income (2010 - 2026)
Perspective Therapeutics' (CATX) quarterly Interest & Investment Income came in at $2.3 million in Q2 2026, up 8.71% year-over-year from $2.2 million in Q2 2025, and up 798.51% quarter-over-quarter from -$336000.0 in Q1 2026.
Powered by 
Analysis
Perspective Therapeutics (CATX) Interest & Investment Income (2010 - 2026) Analysis & Trends
Perspective Therapeutics has disclosed Interest & Investment Income across 17 years of filings, most recently posting $2.3 million for Q2 2026.
- In Q2 2026, Interest & Investment Income rose 8.71% year-over-year to $2.3 million; the TTM figure through Jun 2026 stood at $10.1 million (down 20.97% YoY), while the FY2025 annual figure was $8.1 million, down 22.83% from the prior year.
- Interest & Investment Income came in at $2.3 million for Q2 2026 at Perspective Therapeutics, up from -$336000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $10.5 million in Q4 2024 to a low of -$336000.0 in Q1 2026.
- Average Interest & Investment Income over 5 years is $1.6 million, with a median of $204000.0 recorded in 2023.
- Year-over-year, Interest & Investment Income jumped 16859.68% in 2024 and sank 580.0% in 2026.
- Over 5 years, Interest & Investment Income stood at $561000.0 in 2022, then plunged by 88.95% to $62000.0 in 2023, then jumped by 16859.68% to $10.5 million in 2024, then decreased by 24.4% to $7.9 million in 2025, then slumped by 70.47% to $2.3 million in 2026.
- Per Business Quant data, the three most recent Interest & Investment Income figures were $2.3 million in Q2 2026, -$336000.0 in Q1 2026, and $7.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Perspective Therapeutics | 358.23 Mn | 358.23 Mn | - | 2.35 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.35 Mn |
| Mar 31, 2026 | -336,000.00 |
| Dec 31, 2025 | 7.95 Mn |
| Sep 30, 2025 | 111,000.00 |
| Jun 30, 2025 | 2.16 Mn |
| Mar 31, 2025 | 70,000.00 |
| Dec 31, 2024 | 10.52 Mn |
| Dec 31, 2023 | 62,000.00 |
| Sep 30, 2023 | 204,000.00 |
| Jun 30, 2023 | 294,000.00 |
| Mar 31, 2023 | 374,000.00 |
| Dec 31, 2022 | 561,000.00 |
| Sep 30, 2022 | 197,000.00 |
| Jun 30, 2022 | 57,000.00 |
| Mar 31, 2022 | 29,000.00 |
| Dec 31, 2021 | 31,000.00 |
| Sep 30, 2021 | 31,000.00 |
| Jun 30, 2021 | 32,000.00 |
| Mar 31, 2021 | 21,000.00 |
| Dec 31, 2020 | 5,000.00 |